4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $20,993.40 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $12.84, for a total transaction of $20,993.40. Following the transaction, the insider directly owned 8,617 shares in the company, valued at approximately $110,642.28. This represents a 15.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Wednesday, September 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $13.65, for a total value of $22,317.75.
• On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $14.00, for a total value of $8,176.00.
• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $19,620.00.
• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total value of $19,947.00.

4D Molecular Therapeutics Trading Up 6.6%

Shares of NASDAQ FDMT traded up $0.81 during midday trading on Tuesday, hitting $13.10. The stock had a trading volume of 718,021 shares, compared to its average volume of 854,704. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics, Inc. has a 1-year low of $6.96 and a 1-year high of $16.93. The company has a market capitalization of $723.64 million, a price-to-earnings ratio of -4.98 and a beta of 2.75. The company has a fifty day moving average price of $14.02 and a 200 day moving average price of $11.55.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. On average, analysts predict that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of FDMT. Jupiter Topco LLC purchased a new stake in 4D Molecular Therapeutics during the 2nd quarter worth approximately $76,466,000. BlackRock Inc. purchased a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at approximately $60,463,000. Janus Henderson Group PLC boosted its stake in shares of 4D Molecular Therapeutics by 13.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after buying an additional 611,276 shares during the last quarter. Trails Edge Capital Partners LP purchased a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at approximately $29,631,296. Finally, Bank of America Corp DE acquired a new stake in shares of 4D Molecular Therapeutics during the second quarter worth approximately $14,905,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Chardan Capital reduced their target price on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, October 6th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Bank of America raised their price objective on 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. The Goldman Sachs Group restated a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Thursday. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $28.90.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.